End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.25 CNY | +2.87% | +3.66% | +11.02% |
Jul. 02 | Kelun-Biotech to Buy Equipment from Affiliate | MT |
Jul. 02 | Kelun-Biotech to Buy Equipment from Sichuan Kelun Pharmaceutical's Unit | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.02% | 7.08B | B | ||
+62.66% | 854B | C+ | ||
+40.42% | 636B | B | ||
-4.37% | 361B | C+ | ||
+17.16% | 324B | B- | ||
+9.87% | 301B | C+ | ||
+15.66% | 247B | B+ | ||
+17.90% | 228B | B- | ||
+14.86% | 177B | C+ | ||
+0.45% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002422 Stock
- Ratings Sichuan Kelun Pharmaceutical Co., Ltd.